Radiopharmaceuticals as Novel Immune System Tracers https://ww | Radiation Oncology | Articles preview

Radiopharmaceuticals as Novel Immune System Tracers
https://www.advancesradonc.org/article/S2452-1094(22)00043-4/fulltext?rss=yes

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigms for multiple cancers. However, ICI therapy often fails to generate measurable and sustained antitumor responses, and clinically meaningful benefits remain limited to a small proportion of overall patients. A major obstacle to development and effective application of novel therapeutic regimens is optimized patient selection and response assessment. Noninvasive imaging using novel immunoconjugate radiopharmaceuticals (immuno–positron emission tomography and immuno-single-photon emission computed tomography) can assess for expression of cell surface immune markers, such as programmed cell death protein ligand-1 (PD-L1), akin to a virtual biopsy.